Glow Compound

PLATE VII · THE REGISTER OF SOURCES

GLOW peptide references: every source, set down in the record.

The constituent literature, the recent reviews, and the FDA compounding sources behind every quantitative claim on this site — with DOIs, PMIDs and URLs.

Back to the researchThe regulatory record

About these GLOW peptide references

These GLOW peptide references are the complete cited basis for this digest. The constituent studies (1-7) ground every quantitative claim about GHK-Cu, BPC-157 and TB-500; the 2025-2026 reviews (10-11) supply the current investigational framing; and the FDA sources (12-15) underpin the regulatory and compounding-access record. There is no entry for a trial of the GLOW blend itself, because none exists — every number on this site is a constituent-level or regulatory fact, traced to its source below.

  1. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. ↗
  2. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. ↗
  3. Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research. 2003;21:976-983. ↗
  4. Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95:323-333. ↗
  5. Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364-368. ↗
  6. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opinion on Biological Therapy. 2012;12(1):37-51. ↗
  7. Lee WJ, Sim HB, Jang YH, Lee SJ, Kim DW, Yim SH. Efficacy of a Complex of 5-Aminolevulinic Acid and Glycyl-Histidyl-Lysine Peptide on Hair Growth. Annals of Dermatology. 2016;28(4):438-443. ↗
  8. Research-label formulation convention for the GLOW blend (10 mg BPC-157 / 10 mg TB-500 / 50 mg GHK-Cu per vial), described as a supplier labeling convention rather than a clinically validated dose. Compositional note compiled from the constituent research record; the blend is not a single regulated product and has no controlled trial.
  9. Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine. 2026. ↗
  10. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine. 2025. ↗
  11. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (Category 2 entries for BPC-157; 'Thymosin beta-4, fragment (LKKTETQ), also known as TB-500'; and 'GHK-Cu (for injectable routes of administration)', effective with the September 29, 2023 nominated-substances update.) ↗
  12. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B framework and bulks-list nomination process.) ↗
  13. U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157, KPV, TB-500 and MOTs-C as bulk drug substances being considered for inclusion on the 503A bulks list — a scheduled discussion, not a decision; GHK-Cu is not on this agenda.) ↗
  14. U.S. Food and Drug Administration. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved but Are FDA-Regulated. (Basis for the cosmetic-versus-drug distinction underlying GHK-Cu's dual status: topical 'Copper Tripeptide-1' is regulated under cosmetics rules and not subject to FDA pre-market drug approval, separate from the injectable-drug compounding question.) ↗